Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis
Recruitment status was: Recruiting
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis|
- Anterior chamber inflammation [ Time Frame: 4 weeks after starting treatment ] [ Designated as safety issue: No ]anterior chamber cell grading based on slit lamp microscopy
- probability of relapse-free [ Time Frame: 2 years after treatment ] [ Designated as safety issue: No ]Kaplan-Meier curve of relapse-free probability
|Study Start Date:||October 2011|
|Estimated Study Completion Date:||September 2012|
|Estimated Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
The investigators will enroll 60 patients with positive results of the CMV PCR (polymerase chain reaction) from aqueous humor tapping from January 2006 to June 2011. All the patients (40 men, 20 women) were immunocompetent and diagnosed as symptomatic CMV infection. Their medical records will be reviewed, including demographic data as well as their ophthalmic and medical histories.
The purpose of this study was to evaluate long term efficacy and safety of topical ganciclovir treatment in CMV anterior uveitis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01486693
|National Taiwan University Hospital|
|Principal Investigator:||I-Jong Wang, M.D PhD||National Taiwan University Hospital|